Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;13(4):739-742.
doi: 10.1007/s13679-024-00592-x. Epub 2024 Oct 8.

Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials

Guglielmo Beccuti  1 , Fabio Bioletto  2 , Mirko Parasiliti-Caprino  2 , Andrea Benso  2 , Ezio Ghigo  2 , Alessandro Cicolin  3 , Fabio Broglio  2
Affiliations
Review

Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials

Guglielmo Beccuti et al. Curr Obes Rep. 2024 Dec.

Abstract

Purpose of commentary: This commentary aims to offer a perspective on the effect of tirzepatide on hypoxic burden and provide indirect evidence of cardiovascular risk reduction after tirzepatide for the treatment of obstructive sleep apnea and obesity. It also discusses the role of tirzepatide-induced weight loss in the management of obstructive sleep apnea.

Recent findings: In the SURMOUNT-OSA phase 3 trials, tirzepatide, a new GIP/GLP-1 receptor co-agonist, reduced the apnea-hypopnea index, hypoxic burden, and body weight in adults with moderate-to-severe obstructive sleep apnea and obesity. The change in apnea-hypopnea index is clinically relevant, but its impact on cardiovascular mortality remains unclear. Conversely, hypoxic burden predicts cardiovascular mortality across populations independent of AHI. We attempted to postulate the magnitude of cardiovascular benefits of tirzepatide based on the reduction in hypoxic burden. Tirzepatide treatment for obstructive sleep apnea and obesity seems to result in hypoxic burden values associated with a lower cardiovascular mortality rate and thus might attenuate the negative cardiovascular impact of hypoxic burden.

Keywords: Apnea–hypopnea index; Cardiovascular risk; Hypoxic burden; Obesity; Sleep apnea; Tirzepatide.

PubMed Disclaimer

Conflict of interest statement

G.B. served as consultant for Eli Lilly and Company.

References

    1. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024. 10.1056/NEJMoa2404881. - PMC - PubMed
    1. Patel SR. Entering a new era in sleep-apnea treatment. N Engl J Med. 2024. 10.1056/NEJMe2407117. - PubMed
    1. Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;144(3):e56–67. 10.1161/CIR.0000000000000988. - PubMed
    1. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015–21. 10.1001/jama.284.23.3015. - PubMed
    1. Malhotra A, Heilmann CR, Banerjee KK, Dunn JP, Bunck MC, Bednarik J. Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis. Sleep Med. 2024;121:26–31. 10.1016/j.sleep.2024.06.014. - PMC - PubMed

MeSH terms